What's Happening?
Roche has decided to halt the development of two drugs for Huntington's disease, tominersen and RG6496, following disappointing clinical trial results. Tominersen, developed in collaboration with Ionis, failed to meet efficacy objectives in the phase
2 GENERATION HD2 study, despite achieving biomarker goals. The drug had previously failed in a phase 3 trial. RG6496, another antisense candidate, was discontinued after animal studies indicated it could not be used for long-term treatment. Roche communicated these decisions to patient organizations, emphasizing the importance of focusing on other research avenues.
Why It's Important?
The discontinuation of these drug candidates represents a setback in the search for effective treatments for Huntington's disease, a debilitating neurodegenerative disorder. This decision impacts patients and families hoping for new therapeutic options. It also highlights the challenges pharmaceutical companies face in developing treatments for complex diseases. The move may shift research focus and resources to other promising candidates, such as Roche's gene therapy RG6662, which remains in clinical trials. The decision underscores the importance of transparent communication with the patient community about research progress and setbacks.
